Compositions and methods for improving sexual function
The embodiments include methods of improving sexual function in a male with benign prostatic hyperplasia (BPH), using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a male in need thereof.
1. A method of improving sexual function in a male with benign prostastic hyperplasia (BPH) and sexual dysfunction comprising administering to the male a therapeutically effective amount of the peptide comprising the amino acid sequence in SEQ ID NO. 66 (Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu), wherein the method improves sexual function as determined by comparing the scores of a standardized questionnaire selected from the group consisting of the Brief Male Sexual Functional Inventory, the International Index of Erectile Function, and the Male Sexual Health Questionnaire.
2. The method of claim 1 , wherein the method comprises administration of a therapeutically effective amount of at least one of the peptides as claimed in claim 1 and a carrier.
3. The method of claim 1 , wherein the peptide is administered more than once.
4. The method of claim 1 , wherein the method comprises administration of a therapeutically effective amount of at least one of the peptides as claimed in claim 1 , having at least one and up to 25 additional amino acids flanking either the N-terminus or C-terminus of SEQ ID NO. 66.
5. The method of claim 1 , wherein the peptide is administered by a method selected from the group consisting of orally, subcutaneously, intradermally, intranasally, intravenously, intraprostatically, intramuscularly, intrathecally, intranasally, intratumorally, topically, and transdermally.
6. The method of claim 1 , further comprising administering to the mammal an additional therapeutic agent selected from the group comprising a phosphodiesterase type 5 (PDE5) inhibitor, testosterone, a selective estrogen receptor modulator (SERM), and mixtures thereof.
7. The method of claim 6 , wherein the phosphodiesterase type 5 (PDE5) inhibitor comprises sildenafil, tadalafil, vardenafil and pharmaceutically acceptable salts or solvates thereof.
8. The method of claim 6 , wherein the selective estrogen receptor modulator (SERM) comprises clomiphene, enclomiphene, and pharmaceutically acceptable salts or solvates thereof.
9. The method of claim 1 , wherein the peptide is administered once or twice as an injection and/or an infusion.
10. The method of claim 9 , wherein the period of time between administration of the peptide may vary from about 2 months to about 10 years, or from about 8 months to about 4 years, or from about one year to about two years.
11. The method of claim 1 , wherein improving sexual function comprises eliminating, reducing the effects of, or ameliorating a sexual disorder selected from the group consisting of reduced sexual desire, erectile disorder, premature ejaculation, delayed or inhibited ejaculation, delayed orgasm, anorgasmia, and combinations thereof.
12. The method of claim 1 , wherein the male has no prior history of medical or surgical treatment for BPH.
13. The method of claim 1 , wherein the at least one standardized questionnaire is selected from the Brief Male Sexual Functional Inventory and the International Index of Erectile Function.
14. The method of claim 13 , wherein the at least one standardized questionnaire is selected from the group consisting of the Brief Male Sexual Functional Inventory.